COST-EFFECTIVENESS AND BUDGET IMPACT OF INTERFERON-FREE DIRECT-ACTING ANTIVIRAL (DAA)-BASED REGIMENS FOR CHRONIC HEPATITIS C TREATMENT. THE FRENCH CASE

被引:0
|
作者
Deuffic-Burban, S. [1 ,2 ]
Obach, D. [1 ]
Canva, V. [3 ]
Pol, S. [4 ,5 ]
Roudot-Thoraval, F. [6 ]
Dhumeaux, D. [7 ]
Mathurin, P. [2 ,3 ]
Yazdanpanah, Y. [1 ,8 ]
机构
[1] Univ Paris Diderot, Sorbonne Paris Cite, INSERM, IAME,UMR 1137, Paris, France
[2] Univ Lille, INSERM, Lille Inflammat Res Int, CHU Lille,LIRIC,U995, Villeneuve Dascq, France
[3] CHRU Lille, Hop Huriez, Serv Malad Appareil Digestif & Nutr, Lille, France
[4] Grp Hosp Cochin Hotel Dieu, Unite Hepatol, Paris, France
[5] Univ Paris 05, INSERM, U1016, Paris, France
[6] Hop Henri Mondor, Serv Sante Publ, Creteil, France
[7] Hop Henri Mondor, INSERM, U955, Creteil, France
[8] Hop Bichat Claude Bernard, Serv Malad Infect & Trop, Paris, France
关键词
D O I
10.1016/S0168-8278(16)00793-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
FRI-434
引用
收藏
页码:S470 / S471
页数:2
相关论文
共 50 条
  • [41] Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens
    Amy Puenpatom
    Michael Hull
    Jeffrey McPheeters
    Kay Schwebke
    Clinical Drug Investigation, 2017, 37 : 687 - 697
  • [42] Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens
    Puenpatom, Amy
    Hull, Michael
    McPheeters, Jeffrey
    Schwebke, Kay
    CLINICAL DRUG INVESTIGATION, 2017, 37 (07) : 687 - 697
  • [43] Restoration of natural killer cell activity by interferon-free direct-acting antiviral combination therapy in chronic hepatitis C patients
    Nakamura, Ikuo
    Furuichi, Yoshihiro
    Sugimoto, Katsutoshi
    HEPATOLOGY RESEARCH, 2018, 48 (11) : 855 - 861
  • [44] Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C
    Kawagishi, N.
    Suda, G.
    Onozawa, M.
    Kimura, M.
    Maehara, O.
    Ohara, M.
    Izumi, T.
    Umemura, M.
    Ito, J.
    Nakai, M.
    Sho, T.
    Natsuizka, M.
    Morikawa, K.
    Ogawa, K.
    Sakamoto, N.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S725 - S726
  • [45] COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS IN RUSSIA
    Ignatyeva, V
    Pyadushkina, E.
    Derkach, E., V
    VALUE IN HEALTH, 2019, 22 : S646 - S647
  • [46] Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens
    Harrington, Patrick R.
    Fleischer, Russell
    Connelly, Sarah M.
    Lewis, Linda L.
    Murray, Jeffrey
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (06) : 974 - 977
  • [47] Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials Reply
    Sidharthan, Sreetha
    Kohli, Anita
    Kottilil, Shyam
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (04) : 667 - 668
  • [48] Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies
    Dever, John B.
    Ducom, Julie H.
    Ma, Ariel
    Nguyen, Joseph
    Liu, Lin
    Herrin, Ann
    Groessl, Erik J.
    Ho, Samuel B.
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (06) : 1472 - 1479
  • [49] Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: Do direct-acting antiviral regimens matter?
    Ji, Fanpu
    Yeo, Yee Hui
    Wei, Mike Tzuhen
    Wei, Bin
    Dang, Shuangsuo
    Li, Zongfang
    Nguyen, Mindie H.
    HEPATOLOGY, 2018, 67 (03) : 1180 - 1182
  • [50] Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies
    John B. Dever
    Julie H. Ducom
    Ariel Ma
    Joseph Nguyen
    Lin Liu
    Ann Herrin
    Erik J. Groessl
    Samuel B. Ho
    Digestive Diseases and Sciences, 2017, 62 : 1472 - 1479